AI Article Synopsis

  • - The study aimed to evaluate the vision-related quality of life (VRQoL) in systemic lupus erythematosus (SLE) patients on hydroxychloroquine treatment and identify factors that might affect it.
  • - Involving SLE patients divided into two groups based on the duration of their condition, along with healthy controls, the research utilized various tests and questionnaires to gather data, revealing that healthy individuals reported better VRQoL than those with SLE.
  • - Key factors found to influence VRQoL included disease activity, serum ferritin levels, body-mass index (BMI), age, and best-corrected visual acuity (BCVA), indicating that even without visible eye issues, SLE patients may experience compromised

Article Abstract

Purpose: To assess vision-related quality of life (VRQoL) in patients with systemic lupus erythematosus (SLE) under treatment with hydroxychloroquine (HCQ), and to find the influencing factors.

Methods: Cross-sectional study enrolling SLE patients for less than ten years (Group 1), SLE patients for more than ten years (Group 2), and healthy controls (Group 3). SLE patients should be under treatment with HCQ but without ophthalmological affection. Schirmer test, best-corrected visual acuity (BCVA), axial length (AL) with optical biometry, and swept-source optical coherence tomography-angiography (OCTA) Triton (Topcon) were performed. All participants fulfilled the Impact of Visual Impairment questionnaire, and SLE patients answered the Lupus Impact Tracker (LIT) questionnaire. Additional data were obtained from clinical records.

Results: A totals of 41 eyes (41 patients), 31 eyes (31 patients) and 45 eyes (45 volunteers) were enrolled in the study groups. The mean ages were 41.09 ± 9.56, 45.06 ± 8.47 and 40.25 ± 10.83 years, respectively ( = 0.10). The LIT outcomes were 33.49 ± 20.74 and 35.98 ± 22.66 ( = 0.63), respectively. Group 3 referred to a better VRQoL than Group 2 in all categories and than Group 1 in some of them. A linear regression analysis showed that serum ferritin, SLE activity scales, body-mass index (BMI), age, and BCVA influenced VRQoL. The LIT questionnaire was correlated to two categories of the Impact of Visual Impairment questionnaire (IVI).

Conclusions: Despite no ophthalmological affection, SLE patients refer to poorer VRQoL because of disease activity and a low health-related quality of life, which has a negative influence on VRQoL. This masks the effect of other ophthalmological conditions such as dry eyes. Other variables influencing VRQoL are age and BMI, and BCVA, to a lesser extent.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931292PMC
http://dx.doi.org/10.3390/healthcare12050540DOI Listing

Publication Analysis

Top Keywords

sle patients
20
quality life
12
patients
9
vision-related quality
8
patients systemic
8
systemic lupus
8
lupus erythematosus
8
patients ten
8
ten years
8
years group
8

Similar Publications

Objectives: Previous studies have reported the expansion of CD19+Siglec-10+ B cells in systemic lupus erythematosus (SLE) patients. However, the composition of this cell population, phenotype and characteristics are still unknown.

Methods: We examined this memory B-cell subset's composition and phenotype and determined the SYK and AKT phosphorylation levels by flow cytometry.

View Article and Find Full Text PDF

Acute coronary syndromes in young lupus patients, shifting the view on the old problem.

Clin Exp Rheumatol

December 2024

Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Patients with systemic lupus erythematosus (SLE) are at increased risk of coronary heart disease (CHD). Even though the absolute risk of cardiovascular disease (CVD) among SLE patients increases with advancing age, younger female patients are at the greatest risk of developing acute myocardial infarction (AMI). These young patients are not considered to be at high risk for CVD using traditional risk assessment tools.

View Article and Find Full Text PDF

The Severity of COVID-19 in Systemic Lupus Erythematosus Patient.

Infect Disord Drug Targets

December 2024

Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, 440037, Maharashtra, India.

As of early October 2020, the COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, resulted in approximately 35 million cases and one million fatalities worldwide. Systemic lupus erythematosus (SLE) is an autoimmune disease marked by the generation of pathogenic autoantibodies and a lack of tolerance to nuclear self-antigens. Hypocomple-mentemia, or an abnormal blood complement deficit, is a reliable predictor of infection in SLE patients.

View Article and Find Full Text PDF

Background: Patients with cutaneous lupus erythematosus (CLE) can present with one or multiple different subtypes of CLE. There is limited understanding of the prevalence and associated risk factors for having multiple CLE subtype diagnoses.

Objective: This study characterized the frequency and risk factors for having multiple CLE subtypes.

View Article and Find Full Text PDF

HMGA1 influence on iron-induced cell death in Tfh cells of SLE patients.

Cell Biol Toxicol

December 2024

Department of Rheumatology and Immunology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.

The autoimmune disorder known as Systemic Lupus Erythematosus (SLE) exhibits intricate features with abnormal immune responses leading to tissue injury. The generation of antibodies and the disruption of immune regulation heavily depend on the pivotal function of T follicular helper (Tfh) cells. Iron dysregulation is significant in autoimmune diseases, impacting immune cell function and disease progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!